KRAS and neoplasm: Emerging evidence suggests that somatic mutations in driver genes can modulate tumor immunogenicity; for example, ALK rearrangements, EGFR mutations, and KRAS mutations correlate with immunosuppressive tumor microenvironments (TMEs)[16,17].